Poxviruses: Interfering with interferon

Seminars in Virology

Volumn 8, Issue 5, 1998, Pages 409-418

  Smith, Geoffrey L ^a   Symons, Julian A ^a   Alcamí, Antonio ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Broad species specificity; Interferon receptor; Interferon ; Interferon ; Poxvirus pathogenesis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; GENE PRODUCT; INTERFERON; INTERFERON RECEPTOR;

ANTIVIRAL ACTIVITY; HUMAN; NONHUMAN; POXVIRUS; REVIEW; SPECIES DIFFERENCE; VACCINIA VIRUS; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

POXVIRIDAE; VACCINIA; VACCINIA VIRUS;

EID: 0031803981     PISSN: 10445773     EISSN: None     Source Type: Journal    
DOI: 10.1006/smvy.1997.0145     Document Type: Article

References (96)

1. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B. 147:1957;258-267.
2. Pestka S., Langer J. A., Zoon K. C., Samuel C. E. Interferons and their actions. Annu. Rev. Biochem. 56:1987;727-777.
3. Joklik W. J. Interferons. Virology. 1990;Raven Press, New York. p. 389-410.
4. Farrar M. A., Schreiber R. D. The molecular cell biology of interferon-γ and its receptor. Annu. Rev. Immunol. 11:1993;571-611.
5. Taylor J. Inhibition of interferon action by actinomycin D. Biochem. Biophys. Res. Commun. 14:1964;447-451.
6. Samuel C. E. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology. 183:1991;1-11.
7. Moss B. Poxviridae: the viruses and their replication. Fields B. N., Knipe D. M., Howley P. M. Fields Virology. 1996;2637-2671 Lippincott-Raven, New York.
8. Fenner F., Anderson D. A., Arita I., Jezek Z., Ladnyi I. D. Smallpox and Its Eradication. 1988;World Health Organisation, Geneva.
9. Alcamí A., Symons J. A., Khanna A., Smith G. L. Poxviruses: Capturing cytokines and chemokines. Sem. Virol. 8:1998;419-427.
10. McFadden G., Barry M. How poxviruses oppose apoptosis. Sem. Virol. 8:1998;429-442.
11. Buller R. M. L., Palumbo G. J. Poxvirus pathogenesis. Microbiol. Rev. 55:1991;80-122.
12. Smith G. L. Virus strategies for evasion of the host response to infection. Trends Microbiol. 2:1994;81-88.
13. McFadden G. Viroceptors, virokines and related immune modulators encoded by DNA viruses. 1995;R. G. Landes, Georgetown.
14. Smith G. L. Virus proteins that bind cytokines, chemokines and interferons. Curr. Opin. Immunol. 8:1996;467-471.
15. Spriggs M. K. One step ahead of the game: viral immunomodulatory molecules. Annu. Rev. Immunol. 14:1996;110-130.
16. Upton C., McFadden G. Tumorigenic poxviruses: analysis of the viral DNA sequences implicated in the tumorigenicity of Shope fibroma virus and malignant rabbit virus. Virology. 152:1986;308-321.
17. Goebel S. J., Johnson G. P., Perkus M. E., Davis S. W., Winslow J. P., Paoletti E. The complete DNA sequence of vaccinia virus. Virology. 179:1990;247-266.
18. Massung R. F., Liu L., Qi J., Knight J. C., Yuran T. E., Kerlavage A. R., Parsons J. M., Venter J. C., Esposito J. J. Analysis of the complete genome of smallpox variola major virus strain Bangladesh - 1975. Virology. 201:1994;215-240.
19. Yuen L., Moss B. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc. Natl. Acad. Sci. USA. 84:1987;6417-6421.
20. Smith G. L., Chan Y. S., Howard S. T. Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat. J. Gen. Virol. 72:1991;1349-1376.
21. Colby C., Duesberg P. H. Double-stranded RNA in vaccinia virus-infected cells. Nature. 222:1969;940-944.
22. Boone R. F., Parr R. P., Moss B. Intermolecular duplexes formed from polyadenylylated vaccinia virus RNA. J. Virol. 30:1979;365-374.
23. Rice A. P., Roberts W. K., Kerr I. M. 2-5A accumulates to high levels in interferon-treated, vaccinia virus-infected cells in the absence of any inhibition of virus replication. J. Virol. 50:1984;220-228.
24. Bayliss C. D., Condit R. C. Temperature-sensitive mutants in the vaccinia virus A18R gene increase double-stranded RNA synthesis as a result of aberrant late transcription. Virology. 194:1993;254-262.
25. Simpson D. A., Condit R. C. The vaccinia virus A18R protein plays a role in viral transcription during both the early and late phases of infection. J. Virol. 68:1994;3642-3649.
26. Rice A. P., Kerr S. M., Roberts W. K., Brown R. E., Kerr I. M. Novel 2′,5′-oligoadenylates synthesized in interferon-treated, vaccinia virus-infected cells. J. Virol. 56:1985;1041-1044.
27. Ray C. A., Black R. A., Kronheim S. R., Greenstreet T. A., Sleath P. R., Salvensen G. S., Pickup D. J. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell. 69:1992;597-604.
28. Kettle S., Alcamí A., Khanna A., Ehret R., Jassoy C., Smith G. L. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1β converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis but does not prevent IL-1β-induced fever. J. Gen. Virol. 78:1997;677-685.
29. Ghayur T., Banerjee S., Hugunin M., Butler D., Herzog L., Carter A., Quintal L., Sekut L., Talanian R., Paskind M., Wong W., Kamen R., Tracey D., Allen H. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature. 386:1997;619-623.
30. Upton C., Mossman K., McFadden G. Encoding of a homolog of IFN-γ receptor by myxoma virus. Science. 258:1992;1369-1372.
31. Howard S. T., Chan Y. S., Smith G. L. Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumour necrosis factor receptor family. Virology. 180:1991;633-647.
32. Massung R. F., Jayarama V., Moyer R. W. DNA sequence analysis of conserved and unique regions of swinepox virus: identification of genetic elements supporting phenotypic observations including a novel G protein-coupled receptor homologue. Virology. 197:1993;511-528.
33. Shchelkunov S. N., Blinov V. M., Sandakhchiev L. S. Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms. FEBS Lett. 319:1993;80-83.
34. Mossman K., Upton C., Buller R. M. L., McFadden G. Species specificity of ectromelia virus and vaccinia virus interferon-γ binding proteins. Virology. 208:1995;762-769.
35. Senkevich T. G., Bugert J. J., Sisler J. R., Koonin E. V., Darai G., Moss B. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science. 273:1996;813-816.
36. Alcamí A., Smith G. L. Vaccinia, cowpox and camelpox viruses encode soluble interferon-γ receptors with novel broad species specificity. J. Virol. 69:1995;4633-4639.
37. Blanchard T. J., Alcamí A., Andrea P., Smith G. L. Modified virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use a human vaccine. J. Gen Virol. 79:1998.
38. Essani K., Chalasani S., Eversole R., Beuving L., Birmingham L. Multiple anti-cytokine activities secreted from tanapox virus-infected cells. Microb. Pathog. 17:1994;347-353.
39. Mossman K., Upton C., McFadden G. The myxoma virus-soluble interferon-γ receptor homolog, M-T7, inhibits interferon-γ in a species-specific manner. J. Biol. Chem. 270:1995;3031-3038.
40. Puehler, F. Weining, K. C. Symons, J. A. Smith, G. L. Staeheli, P. Vaccinia virus encoded cytokine receptor binds and neutralizes chicken interferon-γ
41. Lalani A. S., Graham K., Mossman K., Rajarathnam K., Clark-Lewis I., Kelvin D., McFadden G. The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines. J. Virol. 71:1997;4356-4363.
42. Graham K. A., Lalani A. S., Macen J. L., Ness T. L., Barry M., Liu L., Lucas A., Clark-Lewis I., Moyer R. W., McFadden G. The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology. 229:1998;12-24.
43. Alcamí A., Symons J. A., Collins P. D., Williams T. J., Smith G. L. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160:1998;624-633.
44. Karupiah G., Xie Q., Buller R. M. L., Nathan C., Duarte C., MacMicking J. D. Inhibition of viral replication by interferon-γ-induced nitric oxide synthase. Science. 261:1993;1445-1448.
45. Melková Z., Esteban M. Interferon-γ severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology. 198:1994;731-735.
46. Harris N., Buller R. M. L., Karupiah G. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69:1995;910-915.
47. Karupiah G., Blanden R. V., Ramshaw I. A. Interferon-γ is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin-2 infection. J. Exp. Med. 172:1990;1495-1503.
48. Kohonen-Corish N. R. J., King N. J. C., Woodhams C. E., Ramshaw I. A. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-γ Eur. J. Immunol. 20:1990;157-161.
49. Karupiah G., Fredrickson T. N., Holmes K. L., Khairallah L. H., Buller R. M. L. Importance of interferons in recovery from mousepox. J. Virol. 67:1993;4214-4226.
50. Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., Vilcek J., Zinkernagel R. M., Aguet M. Immune response in mice that lack the interferon-gamma receptor. Science. 259:1993;1742-1745.
51. Müller U., Steinhoff U., Reis L. F. L., Hemmi S., Pavlovic J., Zinkernagel R. M., Aguet M. Functional role of type I and type II interferons in antiviral defence. Science. 264:1994;1918-1921.
52. Mossman K., Nation P., Macen J., Garbutt M., Lucas A., McFadden G. Myxoma M-T7, a secreted homolog of the interferon-γ receptor, is a critical virulence factor for the development of myxomatosis in european rabbits. Virology. 215:1996;17-30.
53. Symons J. A., Alcamí A., Smith G. L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell. 81:1995;551-560.
54. Colamonici O. R., Domanski P., Sweitzer S. M., Larner A., Buller R. M. L. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270:1995;15974-15978.
55. Alcamí A., Smith G. L. Receptors for gamma-interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus. Trends Microbiol. 4:1996;321-326.
56. Jenner E. An Enquiry into the Causes and Effects of Variolae Vaccinae, a Disease Discovered in some Western Countries of England, particularly Gloucestershire, and known by the Name of Cow Pox. 1798.
57. Downie A. W. A study of the lesions produced experimentally by cowpox virus. J. Pathol. Bacteriol. 48:1939;361-379.
58. Baxby D. Jenner's Smallpox Vaccine: The Riddle of the Origin of Vaccinia Virus. 1981;Heinemann, London.
59. Fenner F., Wittek R., Dumbell K. R. The Orthopoxviruses. 1989;Academic Press, London.
60. Smith G. L. Vaccinia virus glycoproteins and immune evasion: The Sixteenth Fleming Lecture. J. Gen. Virol. 74:1993;1725-1741.
61. Mayr A., Hochstein-Mintzel V., Stickl H. Abstammung, eigenschaftenund verwendung des attenuierten vaccinia-stammes MVA. Infection. 3:1975;6-16.
62. Smith G. L., Chan Y. S. Two vaccinia virus proteins structurally related to interleukin-1 receptor and the immunoglobulin superfamily. J. Gen. Virol. 72:1991;511-518.
63. Alcamí A., Smith G. L. A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell. 71:1992;153-167.
64. Ueda Y., Ito M., Tagaya I. A specific surface antigen induced by poxvirus. Virology. 38:1969;180-182.
65. Ueda Y., Tagaya I., Amano H., Ito M. Studies on the early antigens induced by vaccinia virus. Virology. 49:1972;794-800.
66. Ueda Y., Morikawa S., Matsuura Y. Identification and nucleotide sequence of the gene encoding a surface antigen induced by vaccinia virus. Virology. 177:1990;588-594.
67. Morikawa S., Ueda Y. Characterization of vaccinia surface antigen expressed by recombinant baculovirus. Virology. 193:1993;753-761.
68. Uze G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: Cloning and expression of its cDNA. Cell. 60:1990;225-234.
69. Novick D., Cohen B., Rubenstein M. The human interferon α/β receptor: Characterisation and molecular cloning. Cell. 77:1994;391-400.
70. Liptáková H., Kontseková E., Alcamí A., Smith G. L., Kontsek P. Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-α 1 and IFN-α2. Virology. 232:1997;86-90.
71. Youngner J. S., Thacore H. R., Kelly M. E. Sensitivity of ribonucleic acid and deoxyribonucleic acid viruses to different species of interferon in cell cultures. J. Virol. 10:1972;171-178.
72. Thacore H. R., Youngner J. S. Rescue of vesicular stomatitis virus from interferon-induced resistance by superinfection with vaccinia virus. II. Effect of uv-inactivated vaccinia and metabolic inhibitors. J. Virol. 56:1973;516-522.
73. Whitaker-Dowling P., Younger J. S. Vaccinia rescue of VSV from interferon-induced resistance: Reversal of translation block and initiation of protein kinase activity. Virology. 131:1983;128-136.
74. Paez E., Esteban M. Resistance of vaccinia virus to interferon is related to an interference phenomenon between the virus and the interferon system. Virology. 134:1984;12-28.
75. Rice A. P., Kerr I. M. Interferon-mediated, double-stranded RNA-dependent protein kinase is inhibited in extracts from vaccinia virus-infected cells. J. Virol. 50:1984;229-236.
76. Whitaker-Dowling P., Youngner J. S. Characterization of a specific kinase inhibitory factor produced by vaccinia virus which inhibits the interferon-induced protein kinase. Virology. 137:1984;171-181.
77. Akkaraju G. R., Whitaker-Dowling P., Youngner J. S., Jagus R. Vaccinia specific kinase inhibitory factor prevents translational inhibition by double-stranded RNA in rabbit reticulocyte lysate. J. Biol. Chem. 264:1989;10321-10325.
78. Watson J. C., Chang H.-W., Jacobs B. L. Characterization of a vaccinia-virus-encoded double-stranded RNA-binding protein that may be involved in inhibition of the double-stranded RNA-dependent protein kinase. Virology. 185:1991;206-216.
79. Chang H.-W., Watson J. C., Jacobs B. L. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 89:1992;4825-4829.
80. Chang H.-W., Jacobs B. L. Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology. 194:1993;537-547.
81. Ho C. K., Shuman S. Mutational analysis of the vaccinia virus E3 protein defines amino acid residues involved in E3 binding to double-stranded RNA. J. Virol. 70:1996;2611-2614.
82. Yuwen H., Cox J. H., Yewdell J. W., Bennink J. R., Moss B. Nuclear localization of a double-stranded RNA-binding protein encoded by vaccinia virus E3L gene. Virology. 195:1993;732-744.
83. Ho C. K., Shuman S. Physical and functional characterization of the double-stranded RNA binding protein encoded by the vaccinia virus E3L gene. Virology. 217:1996;272-284.
84. Beattie E., Denzler K. L., Tartaglia J., Perkus M. E., Paoletti E., Jacobs B. L. Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J. Virol. 69:1995;499-505.
85. Lee S. B., Esteban M. The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. Virology. 199:1994;491-496.
86. Beattie E., Kauffman E. B., Martinez H., Perkus M. E., Jacobs B. L., Paoletti E., Tartaglia J. Host range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes. 12:1996;89-94.
87. Kibler K. V., Shors T., Perkins K. B., Zeeman C. C., Banaszak M. P., Biesterfeldt J., Langland J. O., Jacobs B. L. Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J. Virol. 71:1997;1992-2003.
88. Shors T., Jacobs B. L. Complementation of deletion of the vaccinia virus E3L gene by theEscherichia coliRNAase III gene. Virology. 227:1997;77-87.
89. Chang H.-W., Uribe L. H., Jacobs B. L. Rescue of vaccinia virus lacking the E3L gene by mutants of E3L. J. Virol. 69:1995;6605-6608.
90. Beattie E., Tartaglia J., Paoletti E. Vaccinia-virus encoded eIF-2α homolog abrogates the antiviral effect of interferon. Virology. 183:1991;419-422.
91. Boursnell M. E. G., Foulds I. J., Campbell J. I., Binns M. M. Non-essential genes in the vaccinia virusHindIII K fragment: a gene related to serine protease inhibitors and a gene related to the 37K vaccinia virus major envelope antigen. J. Gen. Virol. 69:1988;2995-3003.
92. Davies M. V., Elroy-Stein O., Jagus R., Moss B., Kaufman R. J. The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded RNA-activated protein kinase and phophorylation of the alpha subunit of eukaryotic initiation factor 2. J. Virol. 66:1992;1945-1950.
93. Beattie E., Paoletti E., Tartaglia J. Distinct patterns of IFN sensitivity observed in cells infected with vaccinia E3L- and K3L-mutant viruses. Virology. 210:1995;254-263.
94. Davies M. V., Chang H.-W., Jacobs B. L., Kaufman R. J. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67:1993;1688-1692.
95. Haig D., McInnes C., Deane D., Lear A., Myatt N., Reid H., Rothel J., Seow H. F., Wood P., Lyttle D., Mercer A. Cytokines and their inhibitors in orf virus infection. Vet. Immunol. Immunopathol. 54:1996;261-267.
96. Asch B. B., Gifford G. E. Fowlpox virus: Interferon production and sensitivity. Proc. Soc. Exp. Biol. Med. 135:1970;177-179.